Skip to main content
Fig. 3 | Clinical Epigenetics

Fig. 3

From: Epigenetic therapy of novel tumour suppressor ZAR1 and its cancer biomarker function

Fig. 3

ZAR1 zinc-finger domain conveys its growth arrest potential. a ZAR1 Mutation mapping found in cancer patients and PTM position reveals association with zinc-finger domain (green; TCGA PanCancer Atlas patient samples; modified). b Quantified cell cycle arrest upon ZAR1 overexpression in HeLa and HCT116. ZAR1-EYFP, ZAR1delZF-EYFP (deleted zinc-finger), and EYFP-empty were overexpressed for 24 h and subsequently analysed by flow cytometry and propidium iodide staining. c Cell cycle distribution of transfected cells and propidium iodide-stained DNA content of cells with gating for cell cycle phases is exemplarily shown for HCT116 cells according to b)

Back to article page